Twice‐daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice‐daily omeprazole, rabeprazole or lansoprazole

Publisher: John Wiley & Sons Inc

E-ISSN: 1365-2036|38|9|1129-1137

ISSN: 0269-2813

Source: ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.38, Iss.9, 2013-11, pp. : 1129-1137

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract